Reuters logo
1 个月内
BRIEF-Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel
2017年6月21日 / 中午12点17分 / 1 个月内

BRIEF-Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel

1 分钟阅读

June 21 (Reuters) - Cardiome Pharma Corp

* Cardiome announces licensing agreement for xydalba™ (dalbavancin hydrochloride) to support planned commercialization in Israel

* Cardiome Pharma Corp - signed an exclusive license and distribution agreement with tzamal medical ltd.

* Cardiome Pharma Corp - tzamal will be responsible for obtaining regulatory and pricing approvals for xydalba from israel's ministry of health

* Cardiome Pharma - cardiome will receive an upfront payment, as well as additional payments, based upon commercial achievements and sales of xydalba

* Cardiome Pharma Corp - additional terms were not disclosed Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below